Keep up to date with every new upload!

Join free & follow C. diff. Spores and More
Share
  • 1 year ago
Encore: Synthetic Biologics - Protecting the Gut Microbiome: A Paradigm Shift in Managing GI Disorde

Encore: Synthetic Biologics - Protecting the Gut Microbiome: A Paradigm Shift in Managing GI Disorde

Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

Comments